公开(公告)号：US20050245232A1

公开(公告)日：2005-11-03

申请号：US10836370

申请日：2004-04-30

申请人： Robert Jakober ,  Barry Henderson

发明人： Robert Jakober ,  Barry Henderson

IPC分类号： G08B27/00 ,  H04L9/00

CPC分类号： G08B27/005

摘要： A method, system, and computer program software for an emergency management and response mission support platform for facilitating communication between a plurality of emergency response and management organizations is provided. In one embodiment, the platform includes an incident management and response unit and a portal. The incident management and response unit coordinates information between a plurality of emergence management and response organizations and provides substantially real-time operational information, such as, for example, location of emergency personnel and assets from a plurality of organizations, emergency response plans, and evacuation plan analysis, and delivers this information to users via a portal which provides a user interface to view content provided by the incident management and response unit. The portal is typically a web portal and the information is provided to any web enabled device, either wireless or wired, connected to the network and authorized to receive the information provided by the platform.

摘要翻译： 提供了一种用于促进多个紧急响应和管理组织之间的通信的应急管理和响应任务支持平台的方法，系统和计算机程序软件。 在一个实施例中，平台包括事件管理和响应单元和门户。 事件管理和应对单位协调多个出现管理和响应组织之间的信息，并提供大量实时的操作信息，例如来自多个组织的应急人员和资产的位置，应急计划和撤离 计划分析，并通过门户将该信息提供给用户，该门户提供用户界面来查看事件管理和响应单元提供的内容。 该门户通常是一个门户网站，并且该信息被提供给连接到网络并被授权接收由平台提供的信息的无线或有线的任何web启用的设备。

公开(公告)号：US20060275816A1

公开(公告)日：2006-12-07

申请号：US11446864

申请日：2006-06-05

申请人： Barry Henderson ,  Richard Cheatham

发明人： Barry Henderson ,  Richard Cheatham

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6809 ,  C12Q1/6837 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/158

摘要： The invention combines a microarray and cell-based screening strategy that enables rapid identification of possible mechanisms underpinning the pharmacology and toxicology of drug candidates. The methods of the invention identified unique properties relating to apoptosis and the anti-inflammatory response elicited by several peroxisome proliferator activated receptor gamma (PPARγ) ligands. The methods illustrate, for example, that PPARγ ligands that are safe and effective drugs (e.g., Actos, Avandia) either do not induce apoptosis or only modestly induce apoptosis. Conversely, PPARγ ligands that have failed clinical development (e.g., Ciglitazone; Day, C., Diabet. Med., 16: 179-192 (1999)) or that have been withdrawn from the market (e.g., Troglitazone (Rezulin)) due to hepatotoxicity are potent inducers of apoptosis. The methods of the invention also illustrate that suppression of gene expression and protein expression for several pro-inflammatory factors by some PPARγ ligands occurs as a consequence of apoptotic induction (i.e., apoptosis produces an anti-inflammatory response). The invention also provides biomarkers for cellular pathways and methods for stratifying patient groups according to their biomarker expression as well as biomarkers that discriminate safe and effective drugs from compounds that have acute toxicities. These biomarkers provide novel insights into the mechanism of action and toxicity for test compounds, including cell death, anti-inflammatory activity, hepatotoxicity, and carcinogenicity. The methods are highly scalable and have broad application from discovery to the clinic, including compound prioritization, predictive pharmacology and toxicology; mechanism of action studies; and prognostic and diagnostic biomarker discovery.

摘要翻译： 本发明结合了微阵列和基于细胞的筛选策略，可以快速鉴定支持候选药物的药理学和毒理学的可能机制。 本发明的方法鉴定了与几种过氧化物酶体增殖物激活受体γ（PPARγ）配体引起的细胞凋亡和抗炎反应有关的独特性质。 所述方法举例说明，安全有效的药物（例如，Actos，Avandia）的PPARγ配体不诱导凋亡或仅适度地诱导细胞凋亡。 相反，临床开发失败的PPARgamma配体（例如，Ciglitazone; Day，C.，Diabet.Med。，16：179-192（1999））或已经从市场撤出（例如，曲格列酮（Rezulin））） 肝毒性是细胞凋亡的有效诱导剂。 本发明的方法还说明，通过一些PPARγ配体抑制几种促炎因子的基因表达和蛋白质表达，这是由于凋亡诱导（即，凋亡产生抗炎反应）的结果。 本发明还提供用于细胞途径的生物标志物和根据其生物标志物表达分层患者组的方法以及从具有急性毒性的化合物区分安全有效的药物的生物标志物。 这些生物标志物为测试化合物的作用机制和毒性提供了新的见解，包括细胞死亡，抗炎活性，肝毒性和致癌性。 这些方法具有高度可扩展性，从发现到诊所具有广泛的应用，包括复合优先级，预测药理学和毒理学; 行动研究机制; 和预后和诊断生物标志物发现。

公开(公告)号：US20120101399A1

公开(公告)日：2012-04-26

申请号：US13332940

申请日：2011-12-21

申请人： Barry Henderson

发明人： Barry Henderson

IPC分类号： A61B5/08

CPC分类号： A61B7/003 ,  A61B5/08 ,  A61B5/1135 ,  A61B5/486 ,  A61B5/6822 ,  A61B5/6831

摘要： A system for determining whether a subject is breathing through his nose or mouth and providing feedback to the user. The feedback may take the form of an alarm signal or an instruction to the user. The system advantageously uses an acoustic sensor placed in the user's suprasternal notch.

摘要翻译： 用于确定受试者是否通过他的鼻子或嘴巴呼吸并向用户提供反馈的系统。 反馈可以采取报警信号或指令的形式给用户。 该系统有利地使用放置在用户的超上限缺口中的声学传感器。

公开(公告)号：US20120090605A1

公开(公告)日：2012-04-19

申请号：US13379750

申请日：2010-06-22

申请人： Liam McDaid ,  Barry Henderson ,  James Harkin

发明人： Liam McDaid ,  Barry Henderson ,  James Harkin

IPC分类号： A61M15/00 ,  G01F15/00 ,  A61M11/04

CPC分类号： A61M15/0086 ,  A61M15/0013 ,  A61M15/0021 ,  A61M15/008 ,  A61M15/0083 ,  A61M15/0088 ,  A61M15/009 ,  A61M2202/064 ,  A61M2205/073 ,  A61M2205/106 ,  A61M2205/3306 ,  A61M2205/3375 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/584 ,  A61M2205/8212

摘要： A medication delivery device for delivering a medicament by inhalation, said device comprising a housing (2) defining a chamber adapted to receive a metered dose of medication from a medication dispensing device, such as a pressurised metered dose inhaler canister or a dry powder inhaler, said chamber having an outlet (4) communicating with a mouthpiece of the device whereby said metered dose of medication can be withdrawn from the chamber via the mouthpiece by inhalation by a patient, said chamber being provided with a moveable wall (5) moveable between a first position and a second position, whereby said moveable wall is arranged to move from its first position to its second position as a patient withdraws a dose of medication from the chamber by inhalation to verify complete inhalation of said dose of medication.FIG. 2

摘要翻译： 一种用于通过吸入递送药物的药物输送装置，所述装置包括限定适于从药物分配装置（例如加压计量吸入器罐或干粉吸入器）接收计量剂量的药物的腔室的壳体（2） 所述腔室具有与所述装置的吸口连通的出口（4），由此所述计量剂量的药物可以经由所述吸嘴通过所述吸嘴从所述患者吸入，所述腔室设置有可移动的壁（5），所述可移动壁可在 第一位置和第二位置，由此当患者通过吸入从腔室中抽出一定剂量的药物以确认完全吸入所述剂量的药物时，所述可移动壁布置成从其第一位置移动到其第二位置。 图。 2

公开(公告)号：US20060234242A1

公开(公告)日：2006-10-19

申请号：US10552642

申请日：2004-04-07

申请人： Richard Cheatham ,  Barry Henderson ,  William Phelps

发明人： Richard Cheatham ,  Barry Henderson ,  William Phelps

IPC分类号： C12Q1/68

CPC分类号： G01N33/5008 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/502 ,  G01N33/5023 ,  G01N33/5044 ,  G01N33/5061 ,  G01N33/5067 ,  G01N33/507 ,  G01N33/5308 ,  G01N33/68 ,  G01N33/6842 ,  G01N33/6845 ,  G01N33/6848

摘要： The identification and evaluation of mRNA and protein targets associated with RNA binding proteins or mRNP complexes is described. In particular, the invention provides methods for identifying RNA binding proteins associated with physiological pathways that participate in glucose and lipid metabolism and mRNAs that exhibit coordinated gene regulation across those M pathways. Candidate targets are provided that are useful for the diagnosis or treatment of diseases related to diseases, such as disease related to aberrant glucose and lipid metabolism, such as, for example, obesity, diabetes, and hypoglycemia.

摘要翻译： 描述了与RNA结合蛋白或mRNP复合物相关的mRNA和蛋白质靶标的鉴定和评估。 特别地，本发明提供了用于鉴定与参与葡萄糖和脂质代谢的生理学途径相关的RNA结合蛋白的方法以及在这些M途径上表现出协调的基因调控的mRNA。 提供了可用于诊断或治疗与诸如肥胖，糖尿病和低血糖异常的疾病相关的疾病的疾病的候选靶。